Size | Price | |
---|---|---|
50mg | ||
100mg | ||
250mg |
ln Vitro |
PhenoxybenzamineHCl (0-100 μM; 96 h) strongly suppresses the growth of U251 and U87MG cells [2]. PhenoxybenzamineHCl (10μM; 24 hours or 72 hours) inhibits the migration and invasion of U251 and U87MG cells [2]. Phenoxybenzamine Hydrochloride (10 μM; 12 h) stimulates LINGO-1 and inhibits the TrkB-Akt pathway [2]. Phenoxybenzamine (0.1 μM-1 mM; 0-16 hours) inhibits hippocampus cell death during oxygen and glucose deprivation [3]. Cell proliferation experiment [2]
|
---|---|
ln Vivo |
Mice administered subcutaneously with phenoxybenzamine hydrochloride (20 nM) twice a day for 26 days demonstrate anticancer effects [2]. In a rat model of severe traumatic brain injury, phenoxybenzamine (1.0 mg/kg; intravenously; once daily for 30 days) shows neuroprotective benefits [3].
|
Cell Assay |
Cell proliferation experiment [2]
Cell Types: U251 and U87MG cell Tested Concentrations: 0.1, 1, 10, 50 and 100 μM Incubation Duration: 96 h Experimental Results: Cell proliferation was Dramatically inhibited, the inhibition rate of U251 cells was 26.5%, and the inhibition rate of U251 cells was 26.5%. is 27.3% for U87MG cells at a concentration of 10 μM. Cell migration experiment [2] Cell Types: U251 and U87MG Cell Tested Concentrations: 10 μM Incubation Duration: 24 h Experimental Results: Obvious migration inhibition was observed, and the inhibition rates of U251 and U87MG were 28.6% and 39.8% respectively. Cell invasion analysis [2] Cell Types: U251 and U87MG Cell Tested Concentrations: 10 μM Incubation Duration: 72 h Experimental Results: The invasion ability of U251 and U87MG was Dramatically weakened, and the number of invasive cells per field of view dropped from 365/field to 132/field for U251. field (36.2%), U87MG is 444/field to 298/field (67.1%). Western Blot Analysis [2] Cell Types: U251 Tested Concentrations: 10 μM Incubation Duration: 12 h Experimental Results: TrkB, |
Animal Protocol |
Animal/Disease Models: nude mice, U87MG tumor model [2]
Doses: 20 nM Route of Administration: subcutaneous injection, 2 days apart, for 26 days. Experimental Results: tumor cell reduction. Animal/Disease Models: Male Wistar rat (350–500 g), traumatic brain injury (TBI) model [3] Doses: 1.0 mg/kg Route of Administration: intravenously (iv) (iv)(iv), one time/day for 30 days Experimental Results: Neurological severity score (NSS) and foot error scores on days 14, 21, and 30. Reduce cognitive impairment associated with severe TBI and reduce expression of pro-inflammatory genes. |
References |
[1]. Habbe N, et al. Urapidil in the preoperative treatment of pheochromocytomas: a safe and cost-effective method. World J Surg. 2013 May;37(5):1141-6.
[2]. Lin XB, et al. Anti-tumor activity of phenoxybenzamine hydrochloride on malignant glioma cells. Tumour Biol. 2016 Mar;37(3):2901-8. [3]. Rau TF, et al. Phenoxybenzamine is neuroprotective in a rat model of severe traumatic brain injury. Int J Mol Sci. 2014 Jan 20;15(1):1402-17. |
Molecular Formula |
C18H22CLNO
|
---|---|
Molecular Weight |
303.83
|
Exact Mass |
303.139
|
CAS # |
59-96-1
|
Related CAS # |
Phenoxybenzamine hydrochloride;63-92-3;Phenoxybenzamine-d5 hydrochloride;1329838-45-0;Phenoxybenzamine (benzyl-2,3,4,5,6-d5) (hydrochloride);1398065-71-8;Phenoxybenzamine-d5;1309283-11-1
|
SMILES |
CC(N(CCCl)CC1=CC=CC=C1)COC2=CC=CC=C2
|
InChi Key |
QZVCTJOXCFMACW-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3
|
Synonyms |
Phenoxybenzamine NSC 37448 NSC37448 NSC-37448A688 A 688A-688
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.2913 mL | 16.4566 mL | 32.9131 mL | |
5 mM | 0.6583 mL | 3.2913 mL | 6.5826 mL | |
10 mM | 0.3291 mL | 1.6457 mL | 3.2913 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.